Expression of lysophosphatidic acid receptors and local invasiveness and metastasis in Chinese pancreatic cancers

Current Oncology

Volumn 19, Issue S1, 2012, Pages 15-21

  Gong, Y L ^a   Tao, C J ^b   Hu, M ^b   Chen, J F ^a   Cao, X F ^a   Lv, G M ^c   Li, P ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c Professional College of Jiangsu Jiankang   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

lpars; Lysophosphatidic acid; pancreatic cancer

Indexed keywords

EID: 84885479510     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1138     Document Type: Article

References (26)

1. Bazzi W, Renon M, Vercherat C, et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. Gastroenterology 2008;135:1698–709.
2. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–15.
3. Liu S, Umezu–Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009;15:539–50.
4. Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (lpa) in malignant ascites stimulates motility of human pancreatic cancer cells through lpa1. J Biol Chem 2004;279:6595–605.
5. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (lpa) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010;91:130–8.
6. Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010;116:1739–50.
7. Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000;73:95–9.
8. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044–9.
9. Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem 1995;270:12949–52.
10. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 1998;12:1589–98.
11. Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, Edg7, for lysophosphatidic acid. J Biol Chem 1999;274:27776–85.
12. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002;1582:257–64.
13. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 2010;102:941–6.
14. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clézardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006;103:9643–8.
15. Jeong KJ, Park SY, Seo JH, et al. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 2008;40:607–16.
16. Schulte KM, Beyer A, Köhrer K, Oberhäuser S, Röher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor Edg4 in differentiated thyroid cancer. Int J Cancer 2001;92:249–56.
17. Kitayama J, Shida D, Sako A, et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004;6:R640–6.
18. Shida D, Fang X, Kordula T, et al. Cross-talk between lpa1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 2008;68:6569–77.
19. Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic acid (lpa) receptors in human colorectal cancer. Lab Invest 2004;84:1352–62.
20. Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008;100:1630–42.
21. Liu S, Umezu–Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009;15:539–50.
22. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein–coupled receptor (lpa2). Oncogene 2004;23:122–9.
23. Yang AH, Ishii I, Chun J. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim Biophys Acta 2002;1582:197–203.
24. Lee SJ, Ritter SL, Zhang H, Shim H, Hall RA, Yun CC. magi-3 competes with nherf-2 to negatively regulate lpa2 receptor signaling in colon cancer cells. Gastroenterology 2011;140:924–34.
25. Hayashi M, Okabe K, Yamawaki Y, et al. Loss of lysophosphatidic acid receptor-3 enhances cell migration in rat lung tumor cells. Biochem Biophys Res Commun 2011;405:450–4.
26. Tian R, Gong Y, Yang J, Duan M, Zhang B. Expressions of tgf2a, egfr in pancreatic carcinoma and their relationship with nervous infiltrative metastasis [Chinese]. J Med Postgraduates 2006;12:1105–9.